The roles of signaling pathways in epithelial-to-mesenchymal transition of PVR

Zhenna Chen, Yan Shao, Xiaorong Li

Tianjin Medical University Eye Hospital, Eye Institute & School of Optometry and Ophthalmology, Tianjin, China

Proliferative vitreoretinopathy (PVR) is an ocular disease characterized by the formation of a dense fibrotic contractile membrane composed of extracellular matrix (ECM) and various cell types in the vitreous cavity and on the epiretinal surface of the retina [1]. PVR occurs mainly in patients after surgery for rhegmatogenous retinal detachment (RRD) and is one of the most common causes of surgical failure, causing tractional retinal redetachment. The incidence of this serious visual complication has remained unchanged, at approximately 5–10%, despite recent advancements in surgery [2,3]. In addition to undergoing surgery, retinal detachment that is untreated for a period of weeks to months, retinal trauma, and a long history of intraocular inflammation are additional risk factors for PVR. As the membrane formation progresses, PVR is categorized into four stages. Grade A is identified by the vitreous haze and/or pigment clumps in the vitreous cavity or on the inferior retina. Grades B to D are identified by retinal morphology, with Grade D further divided into three subclasses [4]. Previously, there were no proposed approaches for preventing the occurrence of PVR, until a growing body of evidence indicated an important role for the epithelial-to-mesenchymal transition (EMT).

EMT is an orchestrated series of events that can occur, for example, during normal embryonic development. In EMT, epithelial cells lose their characteristic epithelial morphology and phenotype and acquire a mesenchymal-like morphology and phenotype [1]. The transdifferentiation is characterized morphologically, for example, by decreased intercellular adhesion and increased cell migration and invasion. Phenotypic changes include decreased expression of epithelial markers such as zonula occludens-1 (ZO-1) and E-cadherin and increased expression of mesenchymal markers such as α-smooth muscle actin (α-SMA), vimentin, and fibronectin [5]. The essential polypeptide ZO-1 is found in tight junction (TJ) complexes and E-cadherin in another type of cell-cell adhesion, adherens junction (AJ). TJ and AJ structures are important in normal epithelial cell structure and function [5-7]. Of the mesenchymal markers, α-SMA is an intracellular cytoskeletal contractile protein involved in cell motility. Vimentin, another intracellular cytoskeletal protein, plays a pivotal role in stabilizing cell structure during migration [5]. Fibronectin, also a marker for fibrosis, is required for microfibril deposition.

EMT mediates the normal physiologic processes of embryogenesis, organ development, and wound healing. However, EMT is also implicated in such pathologic processes as fibrosis, cancer metastasis, and PVR. It has been suggested that various cell types including retinal pigment epithelium (RPE) cells, fibroblast cells, glial cells, and macrophages are components of PVR membranes. RPE cells, a monolayer of tightly connected pigmented cells, are the most important PVR constituents [8]. Normally, RPE cells remain quiescent, maintaining their characteristic morphology and function. The outer blood–retinal barrier (BRB) normally prevents fluid from choroidal vessels from entering the retina. During a pathological condition known as retinal break, the BRB breaks down, and RPE cells become exposed to the vitreous...
that contains various growth factors and cytokines. RPE cells that are activated by the growth factors and cytokines then undergo EMT, and the resulting dedifferentiated RPE cells migrate, proliferate, and transform into (myo)fibroblasts, leading to PVR [7,8]. This suggests that preventing RPE cells from differentiating into (myo)fibroblasts is likely to be an important therapeutic approach to preventing PVR. However, the mechanism of PVR, including the role of EMT signaling pathways, has been obscure. Therefore, we focus on these signaling pathways in this review.

**TGF-β signaling:** RPE cells secrete various growth factors and cytokines including transforming growth factor-beta (TGF-β), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), bone morphogenetic proteins (BMPs), connective tissue growth factor (CTGF), and others. This secretory capacity enables RPE cells to regulate their own growth and that of other surrounding cell types. In recent years, these growth factors have also been implicated as being influential in the development of the PVR membrane [4,8].

TGF-β is overexpressed in the vitreous humor, subretinal fluid, and proliferative membranes in patients with PVR [9,10] and is known to play a crucial role as a potent fibrotic factor. TGF-β signaling involves the canonical Smad signaling pathway and non-canonical pathways. These two types of pathways can interact with each other and contribute to EMT. In the Smad signaling pathway, TGF-β binds to its receptors, types I and II. The type I receptor can directly phosphorylate Smad2 and Smad3. The Smad proteins then associate with Smad4 and translocate to the nucleus where they exert their function. Non-canonical pathways include those of mitogen-activated kinase (MAPK), extracellular signal-regulated kinase 1/2 (ERK1/2), and phosphatidyl inositol 3-kinase (PI3-K)/AKt (also named PKB, protein kinase B)/mTOR (mammalian target of rapamycin) [11,12]. The MAPK non-canonical signaling pathway involves three components—p38 MAP kinase, c-Jun N-terminal kinase (JNK), and p42/44 ERK; each exerts its own biologic function.

TGF-β has three isoforms: TGF-β1, TGF-β2, and TGF-β3. The major isoform is TGF-β2. TGF-β2 concentrations are higher than those of the other isoforms, and there is a strong correlation between TGF-β2 concentration and contractility [13-15]. In a model system that induces EMT in a human retinal pigment epithelial (ARPE-19) cell line with TGF-β2, there was decreased expression of epithelial markers such as E-cadherin and ZO-1 and upregulation of mesenchymal markers such as α-SMA and fibronectin [16,17]. Additional data suggested that TGF-β2 activates other growth factors that contribute to PVR [5,13]. TGF-β1, which was first described as regulating EMT in various epithelial cells [18], may also contribute to EMT, though the TGF-β1 concentration is low and induces a less effective EMT compared with that induced by TGF-β2.

Recently, various proposed approaches for inhibiting EMT of PVR have targeted the TGF-β signaling pathway. TricostatinA (TSA), a class I and II inhibitor of histone-deacetylases (HDACs), is one example [19-21]. HDAC inhibitors have been investigated in various therapeutic indications including inflammation and cancer [22,23] and have antifibrogenic effects in several cell lines. TSA suppresses TGF-β-induced EMT through not only the canonical TGF-β/Smad pathway but also the non-canonical pathways [11]. In addition, p38 MAP kinase, which phosphorylates the middle linker of Smads, also participates in the Smad signaling pathway [24]. Inhibitors of p38 MAP kinase are demonstrated to block TGF-β-induced EMT [9,25]. Taken together, approaches to blocking TGF-β signaling could, therefore, inhibit the process of EMT.

**HGF signaling:** HGF, a pleiotropic growth factor, contributes to the maintenance of retinal homeostasis and normal retinal function [26]. In a serum starvation model, a pathologic condition involving activation of HGF and its receptor c-Met, EMT was induced. This discovery implicated the HGF-signaling pathway as a potential contributor to EMT [27]. However, paradoxically, there were no HGF differences when interleukin and growth factor levels in RRD with or without PVR were compared [28]. Furthermore, some have hypothesized that HGF suppresses the transdifferentiation of RPE [3,29]. Taken together, these findings show that questions remain about the true function of HGF and the HGF/c-Met signaling pathway in PVR. It is possible that stage specificity of growth factor expression is a factor. The observation that HGF is expressed at the highest levels during the middle stage of PVR, probably by unidentified cell types other than RPE and glial cells, could bring a new perspective to the problem [4].

**PDGF signaling:** The PDGF family is composed of five ligands, PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD. These growth factors can each dimerize PDGF receptor (PDGFR) subunits into homodimers or heterodimers (PDGFRα, PDGFRβ, or PDGFRαβ). Many studies have shown an association between PDGF and PVR and reported the activated PDGFRs in membranes of human PVR [30,31]. Though PDGFs are the most abundant of all growth factors and cytokines measured in the vitreous, to date, neutralizing PDGF failed to prevent experimental PVR [3,32,33]. Recent data show that PDGFRα, which can be activated by a much larger spectrum of vitreal growth factors than can the other
receptor subtypes, is required in experimental PVR and inhibition of PDGFRα activation prevents the development of PVR [30,33,34]. The vitreal growth factors are suggested to be non-PDGFRs capable of activating PDGFRs indirectly, thus driving PVR [3,33]. Regarding the nature of this indirect activation, evidence indicates that the non-PDGFRs activate PDGFRs via an intracellular mechanism involving reactive oxygen species (ROS) and a Src family kinase (SFK) [3,35]. These findings suggest that inhibitors of PDGFRs and related pathways would be attractive as a potential target to prevent development of PVR.

Jagged/Notch signaling: The Jagged/Notch signaling pathway participates in many physiologic and pathologic processes including embryonic development, cancer metastasis, and fibrotic diseases [14,16]. In recent years, this pathway has also been implicated in the EMT that occurs in RPE cells. Although this association is not yet certain, accumulating evidence indicates that components of the Jagged/Notch signaling pathway, including Jagged-1, Notch-3, and downstream target genes Hes-1 and Hey-1, are upregulated in RPE cells during TGF-β2-activated EMT [11,14]. Studies modulating the Notch pathway, including through knockdown or overexpression of Jagged-1, showed that the EMT induced by TGF-β2 was closely linked to Jagged/Notch activation [14]. These data indicate that, in addition to the canonical Smad and non-Smad pathways, the Jagged/Notch signaling pathway may also mediate TGF-β2-activated EMT. To further elucidate the pathological mechanism, there is increasing evidence that crosstalk between Smad and Jagged/Notch signaling pathways contributes to TGF-β2-activated EMT [14,16].

Wnt/β-catenin signaling: The Wnt signaling pathway, which is pivotal in cell motility and differentiation, mediates various diseases including PVR. Wnt exerts its function in a paracrine fashion. The canonical Wnt-signaling pathway proceeds as a cascade reaction, initiated when Wnt protein ligands bind to Frizzled and low density lipoprotein receptor-related protein (LRP) receptors on the cell surface. This induces activation of the cytoplasmic phosphoprotein Dishevelled (Dvl) and inhibits the GSK-3/APC/Axin-degradation complex. Dvl activation transduces signals to downstream components, leading to β-catenin accumulation in the cytoplasm and its subsequent translocation to the nucleus. β-Catenin in the nucleus interacts with transcription factor T-cell factor (TCF) and/or lymphoid enhancer factor (LEF), promoting expression of specific genes. Therefore, β-catenin translocation is regarded as being a key molecular event leading to EMT [36].

The Wnt/β-catenin signaling pathway has been primarily studied because of its effects on cadherins, transmembrane glycoproteins that modulate tissue movement [37]. β-Catenin binds to the cytoplasmic domain of cadherins [38-40]. When cadherin binding is disrupted, the release and nuclear translocation of β-catenin results in signaling activation. In this regard, inhibitors of β-catenin signaling may be a promising approach to prevent PVR [38,39].

Hippo signaling: The Hippo-signaling pathway influences cell growth and proliferation as well as contact inhibition. Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are key downstream effectors of the Hippo pathway. TAZ, also referred as WW-domain containing transcriptional regulator 1 (WWTR1), was first reported as a 14–3-3 binding protein [41,42]. TAZ is regarded as a paralog of YAP, and the two share some overlapping functions. However, compared with YAP, TAZ interacts with more DNA-binding transcription factors, including polyomavirus T antigens, TTF-1, TBX5, and Pax3 because of the structural and characteristic differences between the two proteins. TAZ, therefore, can participate in a wide range of biologic processes such as cell proliferation and migration. TAZ can also contribute to human cancers, including breast, ovarian, colorectal, lung, and brain tumors [43]. In recent studies, overexpression of YAP/TAZ-induced EMT during metastatic progression of tumor cells. These reports discussed potential roles of growth factors such as CTGF and the EGFR ligand and speculated on further mechanisms yet to be unraveled [43,44]. Thus far, there has not been any research specifically addressing the role of Hippo signaling in PVR.

Conclusion: PVR, which is characterized by the formation of a fibrotic contractile membrane, still remains a significant post-surgical complication for patients with RRD. It is clear that research toward understanding the complex pathogenic mechanism of PVR is still in its infancy and faces many challenges. However, work in recent decades has led to achievements in understanding several key signaling pathways. These include those pathways activated by TGF-β-, HGF-, and PDGF- as well as Notch-, Wnt/β-catenin-, and Hippo-signaling pathways. Though each has its respective functions, these signaling pathways can also interact with one other, potentially contributing to the pathogenesis of PVR [16]. Among these, the TGF-β-signaling pathway, especially that of TGF-β2, has drawn the most attention in PVR. Inhibiting these signaling pathways would be a potential therapeutic strategy for blocking EMT, thus preventing PVR. However, because growth factors are multifunctional cytokines and their inhibition might cause considerable side effects, individual signaling pathways should be targeted with cautiousness. Clearly, increased understanding of these
complex pathways remains a priority for future prevention and treatment of PVR.

ACKNOWLEDGMENTS

Supported by Natural Science Foundation of Tianjin, China (No.15JCQNJ11400). The authors report no conflicts of interest.

REFERENCES

1. Tamiya S, Liu L, Kaplan HJ. Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Invest Ophthalmol Vis Sci 2010; 51:2755-63. [PMID: 20042656]

2. Li M, Li H, Liu X, Xu D, Wang F. MicroRNA-29b regulates TGF-beta1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells by targeting AKT2. Exp Cell Res 2014; pp.[PMID: 25263462].

3. Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 2014; 40:16-34. [PMID: 24412519].

4. Cui JZ, Chiu A, Maberley D, Ma P, Samad A, Matsubara JA. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye (Lond) 2007; 21:200-8. [PMID: 16531976].

5. Lee H, O’Meara SJ, O’Brien C, Kane R. The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2007; 48:4291-9. [PMID: 17724219].

6. Stevenson BR, Siliciano JD, Moosiker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 1986; 103:755-66. [PMID: 3528172].

7. Palma-Nicolás JP, Lopez-Colome AM. Thrombin induces slug-mediated E-cadherin transcriptional repression and the parallel up-regulation of N-cadherin by a transcription-independent mechanism in RPE cells. J Cell Physiol 2013; 228:581-9. [PMID: 22833386].

8. Li H, Wang H, Wang F, Gu Q, Xu X. Snail involves in the transforming growth factor beta1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells. PLoS ONE 2011; 6:e23322.[PMID: 21853110].

9. Kimoto K, Nakatsuka K, Matsuo N, Yoshioka H. P38 MAPK mediates the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2012; 250:15-23. [PMID: 21858467].

10. Yokoyama K, Kimoto K, Itoh Y, Nakatsuka K, Matsuo N, Yoshioka H, Kubota T. The PI3K/Akt pathway mediates the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2014; 2014:18:646-55. [PMID: 24456602].

11. Xiao W, Chen X, Lui X, Luo L, Ye S, Liu Y. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition in retinal pigment epithelium cells. J Cell Mol Med 2014; 25:829-38. [PMID: 23291002].

12. Parrales A, Lopez E, Lee-Rivera I, Lopez-Colome AM. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation. Cell Signal 2013; 25:829-38. [PMID: 20403150].

13. Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, Hafezi-Moghadam A, Ishibashi T. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci USA 2008; 105:17504-9. [PMID: 18952846].

14. Chen X, Xiao W, Lui X, Zeng M, Luo L, Wu M, Ye S, Liu Y. Blockade of Jagged/Notch pathway abrogates transforming growth factor beta2-induced epithelial-mesenchymal transition in human retinal pig epithelium cells. Curr Mol Med 2014; 14:523-34. [PMID: 24694299].

15. Cheng HC, Ho TC, Chen SL, Liu HY, Hong KF, Tsao YP. Trogliatazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells. Mol Vis 2008; 14:95-104. [PMID: 18253093].

16. Chen X, Xiao W, Wang W, Luo L, Ye S, Liu Y. The complex interplay between ERK1/2, TGFbeta/Smad, and Jagged/Notch signaling pathways in the regulation of epithelial-mesenchymal transition in retinal pigment epithelial cells. PLoS ONE 2014; 9:e96365.[PMID: 24788939].

17. Liang CM, Tai MC, Chang YH, Chen YH, Chen CL, Lu DW, Chen JT. Glucosamine inhibits epithelial-to-mesenchymal transition and migration of retinal pigment epithelial cells in culture and morphologic changes in a mouse model of proliferative vitreoretinopathy. Acta Ophthalmol (Copenh) 2011; 89:e505-14. [PMID: 21457483].

18. Lee J, Choi JG, Joo CK. TGF-beta1 regulates cell fate during epithelial-mesenchymal transition by upregulating survivin. Cell Death Dis 2013; 4:e714.[PMID: 23828577].

19. Huber LC, Distler JH, Moritz F, Hemmatzad H, Hauser T, Michel BA, Gay RE, Matucci-Cerinic M, Gay S, Distler O, Jungel A. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007; 56:2755-64. [PMID: 17665426].

20. Bülow R, Fitzner B, Sparmann G, Emmrich J, Liebe S, Jaster R. Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem Pharmacol 2007; 74:1747-57. [PMID: 17889833].

21. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, Hellemans K, De Bleser P, Yoshiida M, Schuppan D, Rojkind M, Geerts A. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta1-induced fibrogenesis in skin fibroblasts. Exp Cell Res 2002; 278:184-97. [PMID: 12169274].

709
22. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 2005; 10:197-204. [PMID: 15708534].

23. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004; 9:573-82. [PMID: 15314285].

24. Saika S, Yamanaka O, Sumioka T, Miyamoto T, Miyazaki K, Okada Y, Kitano A, Shirai K, Tanaka S, Ikeda K. Fibrotic disorders in the eye: Targets of gene therapy. Prog Retin Eye Res 2008; 27:177-96. [PMID: 18243038].

25. Bakin AV, Rinchert C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002; 115:3193-206. [PMID: 12118074].

26. Jun EJ, Kim HS, Kim YH. Role of HGF/c-Met in serum-starved ARPE-19 cells. Korean J Ophthalmol 2007; 21:244-50. [PMID: 16081931].

27. Grieson I, Heathcote L, Hiscott P, Hogg P, Briggs M, Hagan S. Hepatocyte growth factor/scatter factor in the eye. Prog Retin Eye Res 2000; 19:779-802. [PMID: 11009554].

28. Ricker LJ, Kijlstra A, Kessels AG, de Jager W, Liem AT, Hiscott P, Heathcote L, Grierson I, Porter CA. Modulation of pro- and anti-apoptotic factors in subretinal fluid in rhegmatogenous retinal detachment: a case-control study. PLoS ONE 2011; 6:e19141. [PMID: 21556354].

29. Gamulescu MA, Chen Y, He S, Spee C, Jin M, Ryan SJ, Hinton DR. Transforming growth factor beta2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor. Exp Eye Res 2006; 83:212-22. [PMID: 16563380].

30. Cui J, Lei H, Samad A, Basavanthappa S, Maberley D, Matsubara J, Kazlauskas A. PDGF receptors are activated in human epiretinal membranes. Exp Eye Res 2009; 88:438-44. [PMID: 19032953].

31. Lei H, Velez G, Cui J, Samad A, Maberley D, Matsubara J, Kazlauskas A. N-acetylcycteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol 2010; 177:132-40. [PMID: 20489144].

32. Pennock S, Rheama MA, Mukai S, Kazlauskas A. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am J Pathol 2011; 179:2931-40. [PMID: 22035642].

33. Lei H, Velez G, Howland P, Hirose T, Gilbertson D, Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci 2009; 50:3394-403. [PMID: 19324843].

34. Lei H, Rheama MA, Velez G, Mukai S, Mazlauskas A. Expression of PDGFRalpha is a determinant of the PVR potential of ARPE19 cells. Invest Ophthalmol Vis Sci 2011; 52:5016-21. [PMID: 21642621].

35. Lei H, Kazlauskas A. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor alpha. Mol Cell Biol 2014; 34:110-22. [PMID: 24190966].

36. Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005; 8:727-38. [PMID: 15866163].

37. Becker SF, Langhe R, Huang C, Wedlich D, Kashef J. Giving the right tug for migration: Cadherins in tissue movements. Arch Biochem Biophys 2012; 524:30-42. [PMID: 22387375].

38. Chen HC, Zhu YT, Chen SY, Tseng SC. Wnt signaling induces epithelial-mesenchymal transition with proliferation in ARPE-19 cells upon loss of contact inhibition. Lab Invest 2012; 92:676-87. [PMID: 22391957].

39. Umazume K, Tsukahara R, Liu LH, Fernandez de Castro JP, McDonald K, Kaplan H, Tamiya S. Role of Retinal Pigment Epithelial Cell beta-Catenin Signaling in Experimental Proliferative Vitreoretinopathy. Am J Pathol 2014; 184:1419-28. [PMID: 24656918].

40. Burke JM. Epithelial phenotype and the RPE: Is the answer blowing in the Wnt? Prog Retin Eye Res 2008; 27:579-95. [PMID: 18775790].

41. Xiao H, Jiang N, Zhou B, Liu Q, Du C. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci 2015; 106:151-9. [PMID: 25495189].

42. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28:2426-36. [PMID: 18227151].

43. Yang N, Morrison CD, Liu P, Miccznikowski J, Bshara W, Han S, Zhu Q, Omilian AR, Li X, Zhang J. TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin. Cell Cycle 2012; 11:2922-30. [PMID: 22825057].

44. Wang Q, Xu Z, An Q, Jiang D, Wang L, Liang B, Li Z. TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells. Mol Med Rep 2015; 11:982-8. [PMID: 25354978].